Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL
Clinical trial NCT06832228 · RECRUITING
Trial details
- NCT number
- NCT06832228
- Sponsor
- Zhejiang Cancer Hospital
- Status
- RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-01
- Primary completion
- 2025-09-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.